"Global Dry Eye Syndrome Market 2015-2019" Published

Dry eye syndrome usually results in dryness of eyes due to deficient tear production or quick tear evaporation or deviation in tear uniformity. This syndrome is of two types: aqueous tear deficient dry eye and evaporative dry eye. In aqueous tear deficient dry eye, lacrimal glands do not produce enough tears, whereas meibomian gland dysfunction results in evaporative dry eye. Meibomian glands secrete lipids to slow tear evaporation and maintain tear stability. The symptoms include pain, redness, burning, and fatigue in the eye and decreased tolerance to continuous visual activity. Dry eye syndrome cannot be cured, but symptoms can be controlled. Teardrops and anti-inflammatory drugs are used in the treatment.

Technavio's analysts forecast the global dry eye syndrome market to grow at a CAGR of 4.75% over the period 2014-2019.

Commenting on the report, an analyst from Technavio's team said: "There is no cure for dry eye; current treatment options offer only symptomatic relief. In addition, these therapies do not address the quality of the tears. Thus, there is a need for new drugs that control inflammation with improved efficacy or stimulate mucin and tear secretion. The current pipeline agents are aimed at controlling inflammation and restoring the normal amount of tears. Many of these pipeline candidates exhibit novel mechanisms of action. The approval of late-stage clinical molecules is expected to serve the needs of patients, thereby propelling market growth. These therapies might act alone or in combination with other therapies to provide more effective solutions for dry eye syndrome."

According to the report, changes in lifestyle, especially the increased usage of electronic gadgets such as computers and TV has led to a significant rise in the number of cases of dry eye syndrome. Excessive eye contact with these devices results in strain on the eyes, diminishing visual alertness, and mucosal dryness or eye burning. Continuous and prolonged staring results in an incomplete eye blink, which in turn decreases the stability of the tear film, breaking it and causing ocular discomfort. Therefore, the increased adoption of lifestyle changes leading to dry eye syndrome will drive the market growth.

Further, the report states that reliance on self-medication is a major challenge in the market.

The key players in the Global Dry Eye Syndrome Market are Alcon, Allergan, Otsuka Holdings and Santen Pharmaceuticals while other prominent vendors include Acadia Pharmaceuticals, Aciex, Allostera Pharma, arGentis, Auven Therapeutics (Celtic), Bridge Pharma, Can-Fite and Cellzome

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit - http://www.technavio.com/report/dry-eye-syndrome-market

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H1, 2015
- Global Opthalmic Therapeutic Market 2015-2019
- Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015
- Von Hippel-Lindau Syndrome Global Clinical Trials Review, H2, 2014
- Sjogren's syndrome Global Clinical Trials Review, H1, 2015